A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Clinical trial NCT05232825 · COMPLETED

Trial details

NCT number: NCT05232825
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsing Multiple Sclerosis Primary Progressive Multiple Sclerosis

Start date: 2022-05-03
Primary completion: 2023-03-10
Enrollment: 236

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.